Drug Profile
Succinobucol
Alternative Names: AGI-1067Latest Information Update: 26 Jun 2009
Price :
$50
*
At a glance
- Originator AtheroGenics
- Class Anti-ischaemics; Antihyperlipidaemics; Phenols
- Mechanism of Action Antioxidants; Lipid peroxidation inhibitors; Vascular cell adhesion molecule inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Type 2 diabetes mellitus
Most Recent Events
- 09 Jun 2009 Pharmacodynamics data from an in vitro study presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009)
- 07 Oct 2008 AtheroGenics files for chapter 11 bankruptcy in the US
- 07 Oct 2008 Suspended - Phase-III for Type-2 diabetes mellitus in Eastern Europe (PO)